Last reviewed · How we verify
Bicarbonate de sodium
Bicarbonate de sodium is a Alkalizing agent Small molecule drug developed by Nantes University Hospital. It is currently FDA-approved for Metabolic acidosis, Urinary alkalinization for drug/toxin elimination, Hyperkalemia management (adjunctive).
Sodium bicarbonate acts as a systemic alkalizing agent that increases blood pH and bicarbonate levels to counteract acidosis.
Sodium bicarbonate acts as a systemic alkalizing agent that increases blood pH and bicarbonate levels to counteract acidosis. Used for Metabolic acidosis, Urinary alkalinization for drug/toxin elimination, Hyperkalemia management (adjunctive).
At a glance
| Generic name | Bicarbonate de sodium |
|---|---|
| Sponsor | Nantes University Hospital |
| Drug class | Alkalizing agent |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Metabolic Disorders |
| Phase | FDA-approved |
Mechanism of action
Sodium bicarbonate is a weak base that dissociates in the bloodstream to provide bicarbonate ions, which buffer excess hydrogen ions and raise serum pH. It is used to treat metabolic acidosis by restoring the acid-base balance. Additionally, it can alkalinize urine, which enhances the renal excretion of certain drugs and toxins.
Approved indications
- Metabolic acidosis
- Urinary alkalinization for drug/toxin elimination
- Hyperkalemia management (adjunctive)
- Severe lactic acidosis
Common side effects
- Hypernatremia
- Hypokalemia
- Metabolic alkalosis
- Fluid overload
- Phlebitis (IV administration)
Key clinical trials
- The Effect of Water Physical Exercise Program in Thermal Water and Hydropinotherapy on Cardiovascular Health (NA)
- Oral Sodium Bicarbonate for the Prevention of Labour Dystocia (NA)
- Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma (PHASE2)
- Registry of Pre-mixed Solutions in Critically Ill Patients on the Continuous Renal Replacement Therapy
- Elucidating Hepatic Metabolism in Non-alcoholic Fatty Liver Disease
- Efficacy of Perineural Injection With Dextrose Versus Therapy Conventional Physics in Patients With Bell's Palsy (NA)
- Pharmaco-economic Study of a New Medical Device Performed From the Perspective of the Hospital (PHASE2)
- Preop Hemodialysis or Intraop Ultrafiltration for Patients With Severe Renal Dysfunction Undergoing Open Heart Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bicarbonate de sodium CI brief — competitive landscape report
- Bicarbonate de sodium updates RSS · CI watch RSS
- Nantes University Hospital portfolio CI
Frequently asked questions about Bicarbonate de sodium
What is Bicarbonate de sodium?
How does Bicarbonate de sodium work?
What is Bicarbonate de sodium used for?
Who makes Bicarbonate de sodium?
What drug class is Bicarbonate de sodium in?
What development phase is Bicarbonate de sodium in?
What are the side effects of Bicarbonate de sodium?
Related
- Drug class: All Alkalizing agent drugs
- Manufacturer: Nantes University Hospital — full pipeline
- Therapeutic area: All drugs in Critical Care / Metabolic Disorders
- Indication: Drugs for Metabolic acidosis
- Indication: Drugs for Urinary alkalinization for drug/toxin elimination
- Indication: Drugs for Hyperkalemia management (adjunctive)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing